APM
GMAB icon

Avidity Partners Management’s Genmab GMAB Stock Holding History

Avidity Partners Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
100,000
+8,000
+9% +$240K 0.29% 31
2025
Q4 		$2.83M Sell
92,000
-156,100
-63% -$4.87M 0.82% 28
2025
Q3 		$7.61M Sell
248,100
-401,900
-62% -$9.79M 1.73% 15
2025
Q2 		$13.4M Buy
+650,000
New +$13.3M 2.68% 11

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Avidity Partners Management's GMAB Position: Q1 2026 in Review

Avidity Partners Management increased its Genmab (GMAB) stake by 8.7% in Q1 2026, buying an estimated $240K and bringing the position to 100,000 shares worth $2.67M. The position accounts for 0.29% of the portfolio, ranked #31.

Avidity Partners Management first reported a position in GMAB in Q2 2025 and has held it in 4 quarters since. The position peaked at $13.4M in Q2 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Avidity Partners Management held 100,000 shares of Genmab worth $2.67M as of Q1 2026.
  • Avidity Partners Management bought 8,000 Genmab shares in Q1 2026, an estimated $240K.
  • Genmab made up 0.29% of Avidity Partners Management's portfolio in Q1 2026, its #31 holding.
  • Avidity Partners Management first reported a position in Genmab in Q2 2025 and has held it in 4 quarters since.
  • Avidity Partners Management's Genmab position peaked at $13.4M in Q2 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.